ET-105 FDA Approval Status
Last updated by Judith Stewart, BPharm on Aug 13, 2019.
FDA Approved: No
Brand name: ET-105
Generic name: lamotrigine
Company: Eton Pharmaceuticals, Inc.
ET-105 is an oral liquid formulation of lamotrigine in development as an adjunct therapy for partial seizures, primary generalized tonic-clonic seizures, and generalized seizures of Lennox-Gastaut syndrome in patients two years of age and older.
Development timeline for ET-105
| Date | Article |
|---|---|
| Feb 19, 2020 | Eton Pharmaceuticals Provides Update on ET-105 Program |
| Aug 1, 2019 | Eton Pharmaceuticals Announces FDA Acceptance of New Drug Application for ET-105 |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.